Huang YF, et al. - Researchers attempted to gauge the mortality of patients receiving different adjuvant chemotherapy (ACT) (ie oxaliplatin-based, irinotecan-based, and 5-fluorouracil-only [5FU]) and different treatment frequencies in patients with colorectal liver metastases (CLM) and who underwent liver metastasectomy (LMS). Those who received oxaliplatin-based ACT exhibited greater survival compared to 5FU-only ACT in both synchronous LMS (SLMS) and metachronous LMS (MLMS) patients. Findings also revealed that in MLMS patients, those who received irinotecan-based ACT were more likely to survive than those who received 5FU-only ACT. After LMS, a course of at least 4 to 6 times of ACT was recommended in this patient population.

Methods

· This retrospective cohort study consisted of 2,583 patients with CLM who underwent LMS (including synchronous LMS [SLMS] and metachronous LMS [MLMS]).

· This retrospective cohort study consisted of 2,583 patients with CLM who underwent LMS (including synchronous LMS [SLMS] and metachronous LMS [MLMS]).

· The hazard ratios (HRs) for mortality were attained via Cox proportional hazard model.

· When comparing ACT type, the reference group was 5FU-only ACT

· When comparing ACT frequency, the reference group was treatment for ≤ 3 times.

Results

· A lower risk of mortality in SLMS patients was seen with oxaliplatin-based ACT (HR = 0.78) and receiving ACT for ≥ 4 times (4-6 times, HR = 0.61; 7-9 times, HR = 0.69; 10-12 times, HR = 0.66).

· Oxaliplatin-based ACT (HR = 0.52), irinotecan-based ACT (HR = 0.64), and receiving ACT for 10-12 times (HR = 0.65) correlated with lower risk of mortality in MLMS patients.